List of Excipients in Branded Drug PROVAYBLUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
American Regent Inc	PROVAYBLUE	methylene blue	0517-0374	WATER

ProvayBlue Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

ProvayBlue is a ready-to-use sterile methylene blue injection for acquired methemoglobinemia. Its excipient platform is intentionally narrow: sodium chloride, Water for Injection, and pH adjustment with hydrochloric acid. The commercial opportunity is not a novel excipient claim. It is the combination of sterile manufacturing, controlled pH, light-protective packaging, ready-to-administer presentation, supply reliability, and regulatory know-how for an established but clinically important antidote.

What is ProvayBlue and how does its formulation work?

ProvayBlue contains methylene blue at 5 mg/mL in a sterile intravenous solution. The product is supplied in a single-dose vial, with a labeled dose of 1 mg/kg administered intravenously over five to 30 minutes for acquired methemoglobinemia.[1]

Attribute	ProvayBlue profile
Active ingredient	Methylene blue
Strength	5 mg/mL, equivalent to 0.5%
Dosage form	Sterile intravenous injection
Primary indication	Acquired methemoglobinemia
Route	Intravenous
Regulatory pathway	FDA-approved NDA product
Primary excipients	Sodium chloride and Water for Injection
pH adjustment	Hydrochloric acid may be used
Packaging	Single-dose vial
Key handling issue	Protection from light
Main commercial customers	Hospitals, emergency departments, intensive-care units, operating rooms, poison centers

The formulation uses isotonic saline rather than a complex buffer system. This reduces the number of excipient-related variables in a parenteral product and limits the risk of precipitation, incompatibility, and immune reactions.

What excipients are used in ProvayBlue?

The labeled inactive ingredients are sodium chloride and Water for Injection. Hydrochloric acid is used for pH adjustment where required.[1]

Sodium chloride

Sodium chloride provides tonicity and supports intravenous tolerability. At approximately 0.9% w/v, it places the product close to physiological saline conditions. Sodium chloride is a well-established parenteral excipient with a substantial regulatory history.

Its commercial value is functional rather than proprietary. A formulation using sodium chloride is unlikely to support a broad composition-of-matter patent because the excipient is conventional and the active ingredient is an old small molecule. The strategic value comes from the validated concentration, pH range, sterilization process, container closure system, and stability profile.

Water for Injection

Water for Injection is the vehicle. It must meet compendial requirements for injectable water, including limits on microbial contamination and bacterial endotoxins.

Water quality is a manufacturing control point. Changes in the water system, sterilization process, or filling environment can affect endotoxin control, impurity formation, container compatibility, and batch-release performance.

Hydrochloric acid

Hydrochloric acid is used for pH adjustment rather than as a meaningful therapeutic excipient. pH control matters because methylene blue is sensitive to formulation conditions, light exposure, oxidation-reduction chemistry, and container interactions.

A narrow, validated pH range can support product stability while limiting degradation and color change. The pH adjustment step also creates a process-control opportunity, although it is unlikely to produce meaningful standalone exclusivity.

What formulation properties create commercial value?

ProvayBlue’s commercial value is concentrated in four technical attributes.

Ready-to-use presentation

The product eliminates several steps required for hospital preparation. A ready-to-use vial can reduce pharmacy compounding labor, shorten time to administration, and limit preparation errors during emergency treatment.

For an antidote, speed and availability have direct operational value. Hospitals may maintain the product despite low routine utilization because delayed treatment of severe methemoglobinemia can create acute clinical risk.

Controlled concentration

The 5 mg/mL concentration allows clinicians to calculate a weight-based dose without reconstituting a powder or preparing a diluted stock solution. Dose accuracy matters because excessive methylene blue can worsen hemolysis or produce additional methemoglobinemia, particularly in susceptible patients.

Sterility assurance

The sterile injectable format creates a barrier for new entrants. A competitor must establish validated aseptic processing or terminal sterilization, container closure integrity, particulate controls, endotoxin limits, extractables and leachables data, and stability data.

The manufacturing burden is higher than for a conventional oral generic. A technically simple excipient system does not mean a simple regulatory or manufacturing process.

Light protection

Methylene blue products require light-protective handling. Commercial packaging, labeling, storage, and shipping controls can therefore differentiate a product even when the liquid formulation is similar.

Potential product improvements include:

• Better light-barrier vial or overwrap systems
• Unit-of-use emergency packaging
• Tamper-evident hospital presentation
• Integrated dose calculation labeling
• More robust temperature and light excursion data
• Packaging configurations optimized for automated pharmacy systems

These improvements may support product differentiation without changing the active ingredient.

What patents protect ProvayBlue?

The strongest protection for ProvayBlue is likely regulatory, manufacturing, and commercial rather than broad excipient patent protection.

Methylene blue has been used medically for many decades. A patent directed broadly to methylene blue, sodium chloride, and Water for Injection would face substantial prior-art risk. The more defensible patent targets are narrower:

Potential protection area	Commercial relevance	Likely patent strength
Methylene blue composition of matter	Low	Very low for an old active ingredient
Conventional saline vehicle	Low	Low
Specific pH and stability window	Moderate	Low to moderate, depending on data
Light-protective packaging	Moderate	Moderate if structurally specific
Container closure and oxygen control	Moderate	Moderate
Sterile manufacturing process	Moderate	Moderate if process-specific
Improved impurity profile	Moderate	Moderate to high if linked to clinical or stability benefit
Ready-to-use hospital kit	Moderate	Low to moderate
New dosage form or delivery device	High if clinically useful	Moderate to high
New indication or dosing method	Potentially high	Dependent on clinical evidence

A formulation patent would need to claim more than the use of common saline and injectable water. Useful claim strategies could focus on a defined methylene blue concentration, a specified pH range, impurity limits, light-transmission limits, oxygen content, storage conditions, or container composition. The claims would require comparative stability data and a credible technical effect.

When does ProvayBlue lose exclusivity?

The active ingredient itself has no meaningful new-molecule exclusivity because methylene blue is an established drug. ProvayBlue’s market position depends on the regulatory status of its NDA, any listed patents, applicable non-patent exclusivity, manufacturing capability, and the ability of competitors to obtain approval.

FDA approval of an established active ingredient through an NDA or 505(b)(2)-type strategy can create regulatory barriers even where the active ingredient is old. Those barriers may involve product-specific clinical, pharmacokinetic, quality, manufacturing, or safety data.

The relevant competitive milestones are:

1. FDA approval of an alternative methylene blue injection.
2. ANDA or 505(b)(2) filings by competitors.
3. Paragraph IV certifications against any Orange Book-listed patents.
4. FDA acceptance of the competitor’s abbreviated application.
5. Patent litigation and any resulting stay.
6. Commercial launch after approval or settlement.
7. Hospital formulary conversion and supply qualification.

The current Orange Book record controls whether ProvayBlue has listed patents and what certification obligations apply. Patent expiration should be evaluated from the specific listed patent, not inferred from the age of methylene blue.

What is the Orange Book and Paragraph IV risk for ProvayBlue?

ProvayBlue is an FDA-approved prescription injectable product associated with an NDA. Orange Book exposure depends on whether the NDA sponsor has listed patents covering the product, its formulation, or an approved method of use.

Paragraph IV risk

A competitor could file a Paragraph IV certification if it contends that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For a simple methylene blue injection, likely dispute areas would include:

• Whether a claimed pH range is inventive
• Whether a stability limitation is adequately supported
• Whether the proposed product falls within a formulation claim
• Whether a light-protection or container claim covers the competitor’s package
• Whether a method-of-use claim applies to the proposed label

If no relevant patent is listed, a competitor may avoid Paragraph IV litigation and pursue an approval path based on the applicable FDA requirements.

Regulatory vulnerability

The product may be vulnerable to competition from:

• A generic methylene blue injection
• A 505(b)(2) product with a different concentration
• A prefilled syringe
• A ready-to-use bag or pharmacy vial
• A formulation with improved stability
• An alternative product for methemoglobinemia

The principal barrier is likely not the excipient recipe. It is the ability to demonstrate pharmaceutical equivalence, sterility, stability, labeling compliance, and reliable supply.

What formulation patents could create new commercial opportunities?

Low-volume parenteral systems

A prefilled syringe or ready-to-administer cartridge could reduce dose preparation time. The key development issues would include syringe compatibility, adsorption, extractables and leachables, light protection, and dose accuracy.

Hospital emergency kits

A kit combining the vial with a dosing chart, protective packaging, and administration accessories could target emergency departments, ambulances, intensive-care units, and poison-control response systems. Protection would likely rely on packaging, trademark, and workflow claims rather than a broad excipient patent.

Extended-stability products

A formulation with improved stability under temperature or light excursions could reduce hospital waste. Commercial value would depend on quantified shelf-life extension and transport benefits.

Potential technical approaches include:

• Improved oxygen control
• Alternative vial glass or polymer systems
• Light-blocking secondary packaging
• Optimized headspace management
• Tighter control of degradation impurities
• Validated stability after opening or dilution

Any change to the formulation would require regulatory assessment because injectable products have limited tolerance for excipient changes.

Alternative concentrations

A lower or higher concentration could support pediatric, procedural, or emergency dosing applications. The commercial case would depend on whether the new strength reduces calculation errors or dilution steps without increasing dosing risk.

What manufacturing and IP barriers affect competing methylene blue products?

Competitors face several practical barriers:

Barrier	Impact on entry
Sterile filling capacity	High
Validated endotoxin control	High
Methylene blue impurity control	Moderate to high
Light-sensitive packaging	Moderate
Container compatibility	Moderate
Commercial-scale stability data	High
Hospital vendor qualification	Moderate
Reliable supply of active pharmaceutical ingredient	Moderate
Emergency-product inventory requirements	Moderate
Low market volume	High

A competitor can use the same general excipients and still face substantial execution risk. Small injectable markets often have limited room for manufacturing failures, recalls, or shortages because hospitals require dependable inventory despite modest unit demand.

What are the commercial opportunities for excipient suppliers?

Excipient suppliers have limited opportunity to sell a differentiated ingredient into the existing ProvayBlue formulation. Sodium chloride, Water for Injection, and hydrochloric acid are commodity or highly established materials.

The better opportunities are adjacent:

1. High-purity injectable-grade sodium chloride with strong supply continuity.
2. Water-system validation and microbial-control services.
3. Low-extractables container components.
4. Light-protective vials, overwraps, and labels.
5. Oxygen-controlled packaging.
6. Prefilled syringe systems.
7. Stability-indicating analytical methods.
8. Contract sterile filling and packaging.
9. Hospital-ready emergency kits.
10. Formulation development for alternative methylene blue strengths.

An excipient company could create value by offering a qualified platform rather than a single ingredient. A package combining low-peroxide materials, container compatibility data, light-barrier performance, and regulatory documentation would have greater commercial relevance than a replacement for sodium chloride.

How does ProvayBlue compare with generic methylene blue opportunities?

Factor	ProvayBlue	Generic or alternative entrant
Active ingredient differentiation	Limited	Limited
Excipient differentiation	Narrow	Likely similar
Sterile manufacturing burden	Already established	Significant
Regulatory history	Established NDA	Must establish equivalence or alternative basis
Packaging differentiation	Possible	Possible
Hospital supply value	High	Must prove reliability
Patent leverage	Likely narrow	Can design around narrow claims
Price competition	Exposed if alternatives enter	Primary entry strategy
Clinical switching friction	Moderate	Higher if presentation differs
Shortage opportunity	Strong if supply is constrained	Strong during supply disruptions

The most credible entrant strategy is a low-cost, FDA-compliant injectable with equivalent concentration and familiar packaging. A premium entrant would need a measurable advantage, such as reduced preparation time, improved shelf life, lower waste, or a prefilled presentation.

What is the FDA regulatory status of ProvayBlue?

ProvayBlue is FDA-approved for acquired methemoglobinemia. The product is a sterile prescription injection administered intravenously.[1]

Regulatory issues that affect future excipient or packaging changes include:

• Inactive ingredient identity and concentration
• pH range
• Sterility and endotoxin specifications
• Container closure integrity
• Particulate matter
• Stability under labeled storage conditions
• Light-protection requirements
• Compatibility with infusion materials
• Labeling for glucose-6-phosphate dehydrogenase deficiency and serotonergic drug interactions

Methylene blue has clinically important safety restrictions, including risks involving hemolysis, serotonin toxicity, and use in patients with glucose-6-phosphate dehydrogenase deficiency. A new formulation or delivery system cannot be evaluated solely on excipient performance. It must preserve safe dosing and clear administration instructions.

What is the outlook for licensing and partnerships?

The most attractive partnership structures are likely to involve manufacturing and distribution rather than licensing a novel excipient.

Potential transactions include:

• Regional commercialization rights
• Hospital injectable distribution agreements
• Contract manufacturing arrangements
• Co-development of a prefilled syringe
• Packaging technology licenses
• Supply agreements for emergency medicine portfolios
• Acquisition of an approved injectable product

A partner would likely value FDA approval, validated sterile manufacturing, hospital contracts, shortage performance, and supply continuity more than ownership of a conventional saline formulation.

Key Takeaways

• ProvayBlue uses a simple injectable excipient system based on sodium chloride and Water for Injection, with hydrochloric acid for pH adjustment.
• The formulation itself offers limited broad patent potential because the excipients and active ingredient are well established.
• Stronger protection may arise from pH and impurity specifications, stability profiles, container systems, light protection, and sterile manufacturing processes.
• The principal commercial barriers are sterile production, stability validation, supply reliability, hospital qualification, and regulatory compliance.
• The best product opportunities are prefilled syringes, emergency kits, improved light protection, extended stability, and alternative concentrations.
• Generic competition would likely focus on price and equivalent ready-to-use presentation.
• The commercial value of ProvayBlue is tied to dependable emergency availability rather than excipient novelty.

FAQs

Can ProvayBlue’s sodium chloride excipient be replaced?

A replacement would require formulation, compatibility, stability, sterility, and regulatory evaluation. Sodium chloride is used primarily for tonicity and is difficult to differentiate commercially.

Could a new pH range support a ProvayBlue formulation patent?

A pH range could support claims only if it produces a demonstrated technical benefit, such as improved stability, lower impurity formation, or better container compatibility. A routine pH adjustment is unlikely to provide strong protection by itself.

Is a preservative-containing version of ProvayBlue commercially attractive?

A preservative-containing multidose product would face substantial safety, compatibility, and regulatory issues. A single-dose preservative-free presentation is more consistent with intravenous emergency use.

Could ProvayBlue be developed as a prefilled syringe?

Yes. A prefilled syringe could reduce preparation steps, but development would require studies of adsorption, extractables and leachables, syringe materials, light exposure, dose accuracy, sterility, and shelf life.

Does ProvayBlue have biosimilar risk?

No. Methylene blue is a small-molecule drug, not a biologic. Competitive risk comes from generic or 505(b)(2) injectable products, not biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). ProvayBlue (methylene blue) injection, prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.